EVs engineered to deliver circDIDO1 were successful in inhibiting gastric cancer progression via increased SCOS2 expression, and other types of cancers may benefit from these EVs as well because SOCS2 downregulation is common for many types of cancer; however, EVs loaded with this cargo do not pose a therapeutic use towards leukemia as SOCS2 is already overexpressed in those cancer cells [59]. Here, SOCS2 is linked to gastric cancer.